| Identification | Back Directory | [Name]
L-Proline, compd. with 2-[(4-cyclopropylphenyl)methyl]-4-β-D-glucopyranosylbenzonitrile, hydrate (1:1:1) | [CAS]
1661838-94-3 | [Synonyms]
Velagliflozin proline hydrate
Velagliflozin L-proline Monohydrate
L-Proline, compd. with 2-[(4-cyclopropylphenyl)methyl]-4-β-D-glucopyranosylbenzonitrile, hydrate (1:1:1) | [Molecular Formula]
C28H34N2O7 | [MOL File]
1661838-94-3.mol | [Molecular Weight]
510.59 |
| Hazard Information | Back Directory | [Uses]
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations[1]. | [in vivo]
Velagliflozin proline hydrate (1 mg/kg; p.o.; single dose) increases cholesterol, albumin, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), and urinary glucose excretion, and decreases respiratory exchange ratio in cats[1].
Velagliflozin proline hydrate (0.3 mg/kg; p.o.; once daily for 18 d) is well tolerated and can improve insulin disorders and prevent laminitis in ponies by reducing the high insulin response of dietary non-structural carbohydrates (NSC)[2].
| [IC 50]
SGLT2 | [References]
[1] Hoenig M, et al. Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. J Vet Pharmacol Ther. 2018 Apr;41(2):266-273. DOI:10.1111/jvp.12467
[2] Meier A, et al. The sodium-glucose co-transporter 2 inhibitor velagliflozin reduces hyperinsulinemia and prevents laminitis in insulin-dysregulated ponies. PLoS One. 2018 Sep 13;13(9):e0203655. DOI:10.1371/journal.pone.0203655 |
|
|